These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19537594)

  • 21. [The cardiorenal syndrome: an emerging renal disease].
    Fabbian F
    G Ital Nefrol; 2007; 24(2):108. PubMed ID: 17458823
    [No Abstract]   [Full Text] [Related]  

  • 22. [The state of sympathetic-adrenal system in patients with chronic cardiac insufficiency].
    Nigmatullin RR; Kirillova VV; Dzhordzhikiia RK; Kudrin VS; Klodt PM
    Klin Med (Mosk); 2009; 87(4):32-6. PubMed ID: 19514318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current and novel pharmacological approaches to renal insufficiency in heart failure.
    Hindnavis V; Tang WH
    Minerva Cardioangiol; 2006 Dec; 54(6):753-62. PubMed ID: 17167387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure.
    Davis R; Coukell A; McTavish D
    Drugs; 1997 Jul; 54(1):103-16. PubMed ID: 9211084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature.
    Valika AA; Gheorghiade M
    Heart Fail Rev; 2013 Mar; 18(2):135-40. PubMed ID: 22213014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology of cardiorenal syndrome.
    Mentz RJ; Lewis EF
    Heart Fail Clin; 2010 Jul; 6(3):333-46. PubMed ID: 20630408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies.
    Zannad F; Kessler M; Lehert P; Grünfeld JP; Thuilliez C; Leizorovicz A; Lechat P
    Kidney Int; 2006 Oct; 70(7):1318-24. PubMed ID: 16871247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary hyperaldosteronism in a patient with end-stage renal disease.
    Kazory A; Weiner ID
    Nephrol Dial Transplant; 2007 Mar; 22(3):917-9. PubMed ID: 17127694
    [No Abstract]   [Full Text] [Related]  

  • 29. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
    Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
    J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The confounding issue of comorbid renal insufficiency.
    Fonarow GC; Heywood JT
    Am J Med; 2006 Dec; 119(12 Suppl 1):S17-25. PubMed ID: 17113396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addressing the challenges of cardiorenal syndrome.
    Geisberg C; Butler J
    Cleve Clin J Med; 2006 May; 73(5):485-91. PubMed ID: 16708717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of congestive heart failure: experience with fosinopril.
    Blumenthal M
    Am J Hypertens; 1997 Oct; 10(10 Pt 2):289S-298S. PubMed ID: 9366286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension.
    Wagstaff AJ; Davis R; McTavish D
    Drugs; 1996 May; 51(5):777-91. PubMed ID: 8861547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of dobutamine on renal sympathetic activity in human heart failure.
    Al-Hesayen A; Parker JD
    J Cardiovasc Pharmacol; 2008 May; 51(5):434-6. PubMed ID: 18398381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Influence of chronic cardiac failure severity on the course of comorbid type 2 diabetes mellitus].
    Narusov OIu; Lapina IuV; Mareev VIu; Bolotina MG; Shestakova MV; Masenko VP; Baklanova NA; Belenkov IuN
    Ter Arkh; 2009; 81(9):52-7. PubMed ID: 19827654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Broken pump or leaky filter? Renal dysfunction in heart failure a contemporary review.
    Petrie CJ; Mark PB; Weir RA
    Int J Cardiol; 2008 Aug; 128(2):154-65. PubMed ID: 18191240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of peripheral microvascular dysfunction during long-term treatment with the angiotensin-converting enzyme inhibitor fosinopril in congestive heart failure.
    Galatius S; Wroblewski H; Sørensen V; Haunsø S; Nørgaard T; Kastrup J
    J Card Fail; 1999 Mar; 5(1):17-24. PubMed ID: 10194656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria.
    van der Harst P; Asselbergs FW; Hillege HL; Voors AA; van Veldhuisen DJ; van Gilst WH;
    Am J Cardiol; 2008 Jul; 102(2):223-5. PubMed ID: 18602526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cardiorenal syndrome in heart failure.
    Damman K; Voors AA; Navis G; van Veldhuisen DJ; Hillege HL
    Prog Cardiovasc Dis; 2011; 54(2):144-53. PubMed ID: 21875513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peritoneal dialysis in patients with primary cardiac failure complicated by renal failure.
    Cnossen TT; Kooman JP; Konings CJ; Uszko-Lencer NH; Leunissen KM; van der Sande FM
    Blood Purif; 2010; 30(2):146-52. PubMed ID: 20847552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.